Intrexon Corp XON:NASDAQ

Last Price$7.37Cboe Previous Close - Real-Time Last Sale as of 4:00PM ET 7/16/19
Cboe Real-Time Quotes
Today's Change+0.005(0.07%)
Bid (Size)$7.35 (400)
Ask (Size)$7.46 (400)
Day Low / High$7.32 - 7.55
Volume15.00
 

View Biotechnology IndustryPeer Comparison as of 07/16/2019

 

Intrexon Corp ( NASDAQ )

Price: $7.37
Change: +0.005 (0.07%)
Volume: 15.00
4:00PM ET 7/16/2019
 
 

Rubius Therapeutics Inc ( NASDAQ )

Price: $14.86
Change: +0.05 (0.34%)
Volume: 137.5 K
3:59PM ET 7/16/2019
 
 

Esperion Therapeutics Inc ( NASDAQ )

Price: $44.26
Change: +0.02 (0.05%)
Volume: 489.00
3:59PM ET 7/16/2019
 
 

Epizyme Inc ( NASDAQ )

Price: $12.73
Change: -0.20 (1.55%)
Volume: 571.4 K
9:30AM ET 7/17/2019
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $18.83
Change: +0.05 (0.27%)
Volume: 836.00
4:00PM ET 7/16/2019
 

Read more news Recent News

Insider Trends: Intrexon Insider Receives Stock Award, Buy Trend Intact
4:46PM ET 7/02/2019 MT Newswires

Randal J Kirk, 10% Owner, Director and CEO, received a stock award of 174,954 Intrexon (XON) shares Jun 28, 2019 which had an approximate daily closing...

Intrexon Moves To Next Stage Phase Ib/IIa Clinical Study For Type 1 Diabetes Investigational Drug
11:59AM ET 7/01/2019 MT Newswires

Intrexon (XON) said Monday that it will proceed to the next stage of the phase Ib/IIa clinical trial for investigational drug AG019 for the treatment of...

Intrexon Doses First Patient With Investigational Leukemia Drug
8:13AM ET 6/26/2019 MT Newswires

Intrexon (XON) said its subsidiary Precigen has dosed its first patient with PRGN-3006, an investigational drug for the treatment of relapsed or refractory...

Intrexon Shares Surge Almost 10% Off-Halt on $100 Million License Deal With Surterra Wellness
10:41AM ET 6/18/2019 MT Newswires

Intrexon (XON) shares surged almost 10% off a trading halt Tuesday morning after the bioengineering company agreed to a $100 million exclusive licensing...

Company Profile

Business DescriptionIntrexon Corp. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. View company web site for more details
Address20374 Seneca Meadows Parkway
Germantown, Maryland 20876
Phone+1.301.556.9900
Number of Employees882
Recent SEC Filing07/02/20194
Chairman & Chief Executive OfficerRandal J. Kirk
Chief Operating OfficerThomas Bostick
Chief Financial & Accounting OfficerRick L. Sterling
Chief Science OfficerThomas David Reed

Company Highlights

Price Open$7.50
Previous Close$7.36
52 Week Range$3.95 - 19.94
Market Capitalization$1.2 B
Shares Outstanding160.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/08/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.35
Beta vs. S&P 500N/A
Revenue$160.6 M
Net Profit Margin-363.19%
Return on Equity-118.72%

Analyst Ratings as of 07/05/2019

Buy
1
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset